Brainstorm Cell Therapeutics (BCLI) News Today → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free BCLI Stock Alerts $0.58 +0.01 (+1.05%) (As of 05:32 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 6:00 AM | prnewswire.comBrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwnMay 17, 2024 | americanbankingnews.comShort Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Grows By 5.5%May 16, 2024 | msn.comBrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02May 16, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Share Price Crosses Above Two Hundred Day Moving Average of $0.36May 16, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.comMay 15, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateApril 17, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 17, 2024 | msn.comBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical OfficerApril 17, 2024 | msn.comBrainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55April 17, 2024 | marketwatch.comBrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical ChiefApril 11, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 11, 2024 | finance.yahoo.comBCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…April 11, 2024 | prnewswire.comBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 10, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 10, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 9, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 9, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 8, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Provide Update on NurOwn ProgramApril 1, 2024 | benzinga.comBrainstorm Cell: Q4 Earnings InsightsApril 1, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate UpdateMarch 25, 2024 | msn.comWhy Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 6, 2024 | finance.yahoo.comBCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…February 29, 2024 | investing.comBrainStorm details Phase 3b trial for ALS treatment NurOwnFebruary 27, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceFebruary 27, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceFebruary 25, 2024 | finance.yahoo.comBCLI Mar 2024 1.500 callFebruary 23, 2024 | marketwatch.comBrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDAFebruary 23, 2024 | msn.comBrainStorm submits SPA request to FDA for Phase 3 study designFebruary 23, 2024 | prnewswire.comBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSFebruary 16, 2024 | wsj.comBrainstorm Cell Therapeutics Inc.February 13, 2024 | uk.investing.comBrainstorm Cell Therapeutics Inc (BCLI)February 13, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics to Present at European Life Sciences CEO ForumFebruary 1, 2024 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (BCLI)January 14, 2024 | seekingalpha.comBCLI Brainstorm Cell Therapeutics Inc.January 1, 2024 | businesswire.comBCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before ...December 26, 2023 | marketwatch.comBrainstorm Cell Therapeutics Shares Rise 11% on Patent ApprovalsDecember 26, 2023 | msn.comBrainStorm Cell Therapeutics spikes on patent winsDecember 26, 2023 | finance.yahoo.comBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder TreatmentsDecember 22, 2023 | barrons.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming DeadlineDecember 20, 2023 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Issues 2023 Letter to ShareholdersDecember 20, 2023 | finance.yahoo.comBrainStorm Issues 2023 Letter to ShareholdersDecember 17, 2023 | morningstar.comBCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud LawsuitDecember 16, 2023 | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIDecember 8, 2023 | finance.yahoo.comBCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwnDecember 7, 2023 | msn.comWhy BrainStorm Cell Therapeutics Shares Are FallingDecember 7, 2023 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALSNovember 28, 2023 | morningstar.comBrainstorm Cell Therapeutics Inc BCLINovember 26, 2023 | barrons.comINVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BCLINovember 23, 2023 | barrons.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline -- BCLI Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” BCLI Media Mentions By Week BCLI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCLI News Sentiment▼0.460.44▲Average Medical News Sentiment BCLI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCLI Articles This Week▼32▲BCLI Articles Average Week Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRZN News Today PLUR News Today ACHL News Today SABS News Today INKT News Today QNCX News Today CYTH News Today OKYO News Today NKGN News Today DYAI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCLI) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsThis military-backed stock “owns” AI marketPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
